Introduction
Quinazoline-4(3H)-one ring system has been consistently regarded as promising privileged structural icon owing to its pharmacodynamic versatility in many of its synthetic derivatives as well as in several naturally occurring alkaloids isolated from animals, families of plant kingdoms and micro-organisms [1] - [3] .
A systematic perpusal of literature, reveals that quinazoline derivatives encompass a broad spectrum of pharmaceutical activity profile such as antitumor [4] - [10] , anti-HIV [11] - [13] , antimicrobial [14] - [16] , antibacterial, anti-inflammatory [17] - [20] , CNS activity [21] - [23] and cardiovascular activity [24] [25] . The quinazoline nucleus is the scaffold of many antitumor drugs mainly acting as inhibitors of tyrosine kinase receptor (TKR) [26] . Over expression of the receptors has been observed in a number of cancers such as breast, ovarian, colon and prostate cancer. Therefore, blocking of tyrosine kinase activity represents a rational approach to cancer therapy [27] - [34] . Also quinazoline derivatives have a therapeutic potential as an anti-invasive agent with potential activity in early and advanced solid tumors, metastatic bone disease and leukemia [35] . So the quinazoline ring is considered as one of the major classes of benzoheterocyclic compounds that have drawn much attention in the field of cancer chemotherapy besides other pharmacological activities [27] - [29] . Moreover, many 4-quinazoline derivatives revealed potent anticancer activity mediated through the inhibition of dihydrofolate reductase enzyme (DHFR) [30] [31] or through inhibition of chki kinase [32] .
Results and Discussion

Chemistry
2-Methyl-quinazolin-4-one was synthesized from the fusion of anthranilic acid with thioacetamide [36] which was utilized as a building unit for novel quinazoline and fused quinazolinone compounds "(Scheme 1)". The extent of the pharmacological effect of a quinazolinone derivative depends on the active group which is attached to it. Recently, several scientists have elucidated that in quinazolinone system sites like position 2 and 3, can be suitably modified by the introduction of various heterocyclic moieties to show excellent pharmacological results [37] [38] . 
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A known procedure for building up such heterocyclic system is based on cyclization of o-chlorobenzoyl chloride with 2-methyl-quinazolin-4(3H)-one 1 in dry THF. The reaction stopped at the stage of formation of 2-[2-(2-chlorophenyl)-2-oxoethyl]quinazolin-4(3H)-one 2. This could be explained in the first place by steric hindrance of the o-substituent for optimal position of the reacting groups. We attempted to decrease the effect of the latter by heating compound 2 in THF for 2h. However under this reaction condition, cyclization occurred readily to yield 5H-quinolino[2,1-b]quinazolin-5, 12(6H)-dione 3.
The 1 H-NMR spectrum of compound 2 revealed a singlet at δ 4.33 ppm attributed to CH 2 protons and a deuterium oxide exchangeable singlet at δ 7.73 ppm due to the NH proton. While, 1 H-NMR spectrum of compound 3 showed a singlet at δ 2.49 ppm assigned to CH 2 protons and lacked any deuterium oxide exchangeable signals of its precursor.
Attempts to carry out a similar conversion of compound 1 into 4 by refluxing in THF are unsuccessful. However, the cyclic quinolono [2,1-b]quinazoline 4 was obtained through the reaction of compound 1 with 2-chlorobenzaldehyde in glacial acetic acid/sodium acetate. In this case, isolation of the intermediate 4' was difficult because of its high reactivity which led directly to the cyclic product 4.
Pyrrolo[2,1-b]quinazolindione derivative 5 was prepared by the reaction of compound 1 with chloroacetyl chloride in dry THF. The reaction is assumed to proceed through chloroacetylation of compound 1 at the 2-position followed by intramolecular cyclization on N 3 -NH function with elimination of a hydrochloride molecule to give the target compound 5.
1
H-NMR spectrum of compound 5 showed two singlets at δ 2.08, 2.49 ppm each integrated for two protons attributed to two pyrrolo methylene protons.
Our attention was drawn to the earlier discovery by scientists that modification of methyl group present at the second position of 4(3H)-quinazolinone into other chemical intities yielded structural analogues with appreciable biological activity [39] [40] "(Scheme 2)". Therefore, compound 1 was condensed with 4-chlorobenzaldehyde in glacial acetic acid/sodium acetate to afford the chalcone derivative 6 [41] . Chlorination of compound 6 with phosphorous oxychloride was reported to give [42] poor yields of impure chlorinated product. However, H-NMR spectrum of compound 11 revealed a singlet at δ 3.46 ppm due to SCH 2 protons. The 1 H-NMR spectrum of compounds 12 revealed a singlet at δ 7.49 ppm due to CH-thiazole proton.
However, tricyclic systems in which the quinazoline ring was condensed with imidazole ring have not been adequately studied "(Scheme 4)". Therefore our goal was directed to synthesize imidazoquinazoline derivatives through condensation of compound 8 with phenacyl chloride in ethanol, which afforded quinazolin-3-ium chloride derivative 14 and imidazo[1,2-c]quinazoline derivative 15 according to the mechanism suggested in the literature [45] . The first step of this process involved the addition of a phenacyl chloride molecule on N-3 position to form the corresponding quinazolinium derivative 14 which underwent cyclization under the same experimental conditions to give the imidazoquinazoline derivative 15. The 1 H-NMR spectrum of compound 14 showed a singlet at δ 3.63 ppm due to CH 2 protons, in addition to two deuterium oxide exchangeable singlets at δ 5.18 and 12.33 ppm due to NH 2 protons and OH tautomer proton; respectively. While the 1 H-NMR spectrum of compound 15 revealed a singlet integrated for one proton at δ 7.96 ppm due to CH-imidazole.
Moreover, acylation of the amino group of compound 8 with chloroacetyl chloride under anhydrous conditions which underwent intramolecular cyclization on the ring to yield the cyclized product imidazo[1,2-c]-quinazolinone derivative 16. In the case of chloroacetyl chloride, the isolation of the intermediate 16' was difficult due to its high reactivity which led directly to the cyclic product 16. The 1 H-NMR spectrum of compound 16 revealed a singlet at δ 3.55 ppm due to CH 2 protons of imidazole moiety and another singlet at δ 7.50 ppm attributed to the imidazole = CH-tautomer. In addition to a deuterium oxide exchangeable singlet at δ 8.51 ppm corresponding to OH tautomer.
Recently, several biological activities have been reported for [1, 2, 4] triazino [4,3-c] quinazolines [46] , so our aim was extended to the development of different synthetic methods for novel [1, 2, 4] triazino [4,3- c]quinazolines 17 and 18 and investigation of their cytotoxicity and antitumor activity "(Scheme 5)". Therefore, condensation of compound 9 with benzoin and with chloroacetyl chloride were applied to furnish the target compounds 17 and 18; respectively. The 1 H-NMR spectrum of compound 17 revealed a singlet at δ 6.02 ppm due to the triazine C 5 -proton. While, the 1 H-NMR spectrum of compound 18 showed a singlet at δ 4.25 ppm due to the triazine CH 2 protons, in addition to a deuterium oxide exchangeable singlet at δ 12.20 ppm attributed to NH proton. Furthermore, from our survey in the literature, it was found that, a new series of quinazoline compounds was designed in such a way to accommodate the isothiocyanates, Schiff's bases and amine bridges at positions 2, 3 or 4 of the quinazoline ring. Isothiocyanate, Schiff's base and amide functions are known to contribute in the enhancement of the antitumor activity [4] . The reaction of phenyl isothiocyanate with compound 9 afforded hydrazine carbothioamide derivative 19. The 1 H-NMR spectrum of compound 19 showed a deuterium oxide exchangeable singlet at δ 3.98 ppm due to two NH protons that are attached to C=S function and a deuterium oxide exchangeable singlet at δ 11.08 ppm due to NH proton attached to the quinazoline ring which is more deshielded by the nitrogens of the quinazoline ring. The thiosemicarbazide derivative 19 underwent oxidative cyclization by stirring with bromine to yield [1, 2, 4, 5] tetrazino [1,6-c] quinazoline thione derivative 20. The 1 H-NMR spectrum of compound 20 showed a deuterium oxide exchangeable singlet at δ 4.00 ppm due to NH proton.
Moreover, the reaction of compound 9 with 4-chlorobenzaldehyde in presence of piperidine furnished the Schiff's base 21 "(Scheme 6)". The Schiff's base 21 was used as a good starting material for preparation of several quinazoline derivatives. Among which its reaction with thioglycolic acid in presence of anhydrous zinc chloride to furnish the thiazolidinone derivative 22. Furthermore, the reaction of the Schiff's base 21 with chloroacetyl chloride in presence of triethylamine as a base afforded azetidinone derivative 23. The 1 H-NMR spectrum of compound 23 revealed two doublets at δ 4.06 and 4.30 ppm attributed to CH-C 6 H 4 -Cl and CH-Cl of the azetidine ring; respectively. In addition to a deuterium oxide exchangeable singlet at δ 10.68 ppm attributed to NH proton. Moreover, a group of Slovak's scientists reported that [1, 2, 4] triazolo [4,3-c] quinazoline derivatives possess considerable in vitro antitumor activity [46] . So we synthesized [1, 2, 4] triazolo [4,3-c] quinazoline compound 24 through the cyclization of the Schiff's base 21 in glacial acetic acid/sodium acetate.
Finally, our work was extended to react 4-chloroquinazoline derivative 7 with several primary and secondary amines preparing a series of promising derivatives in order to compare their biological activities "(Scheme 7)". Focusing on setting up a simple, cheap, fast and efficient synthesis; the reaction of compound 7 with the primary amine, 2-aminoethanol was accomplished by fusion with excess amine reducing as much as possible both reaction time and temperature so as to preserve the styryl group from reacting. This rapid reaction protocol resulted in the formation of the secondary aminoquinazoline derivative 25 in good yields. compound 25 showed a multiplet at δ 3.66 -3.71 ppm integrated for four protons corresponding to two CH 2 protons and two deuterium oxide exchangeable singlets at δ 4.40 and δ 12.25 ppm attributed to OH and NH protons, respectively. Moreover, the substrate 7 was also reacted very easily with secondary amines such as dimethylamine and pyrrole by the same manner as aminoethanol to yield tertiary amino quinazolines 26 and 27; respectively in very good yields. Furthermore, compound 7 was reacted with anthranilic acid in glacial acetic acid to afford the polycyclic quinazoline derivative 28 while hot, while the reaction filtrate yielded the open chain secondary aminoquinazoline derivative 29 that bears a free carboxylic group which could possibly alter the biological properties including cytotoxic activity [47] . However, the reaction is expected to proceed through formation of the secondary aminobenzoic acid derivative 29 first which carried out intramolecular dehydration reaction leading to the cyclic quinazolinoquinazoline derivative 28. 
Biology
The six dose growth inhibition percent and the IC 50 values of the tested compounds (2 -29) against liver HepG2 and breast MCF-7 cell lines are represented in Tables 1 and 2; respectively. The thiourea derivative 10 exhibited strong anticancer activity against liver cancer cell line about half the activity of doxorubicin (IC 50 98 µM/L against MCF-7 cell line; respectively. It is to be noted that, the presence of a phenyl thiosemicarbazide side chain attached to the C 4 -quinazoline ring as in compound 19 exhibited marked anticancer activity against both HepG2 and MCF-7 cell lines exerting IC 50 18 .79 and 13.46 µM/L; respectively. However, incorporating N-azetidinone-4-amino moiety to the quinazoline back bone as in compound 23 resulted in improvement in activity against both HepG2 and MCF-7 cell lines which exhibited slightly better anticancer activity against HepG2 (IC 50 7 .09 µM/L) than the reference drug doxorubicin (IC 50 8 .55 µM/L). While, it showed comparable activity to that of doxorubicin (IC 50 8 .90 µM/L) against MCF-7 exerting IC 50 11 .94 µM/L.
Furthermore, fusion of triazole ring to quinazoline nucleus as in compound 24 resulted in marked increase in activity against both HepG2 and MCF-7 cell lines exerting IC 50 10 .58 and 10.82 µM/L; respectively which represent a strong anticancer agent against these two cell lines (Figures 1 and 2) . Moreover, the presence of 2-amino benzoic acid moiety on the C 4 -quinazoline ring as in compound 29 exhibited remarkable increase in activity towards HepG2 cell line showing IC 50 19 .95 µM/L.
Computer Aided Docking
Five representative active anticancer compounds 18, 19, 20, 23 and 24 were subjected to docking using Molecular Operating Environment (MOE) program [48] on the 3D structure of two enzymes, namely; thymidylate synthase (TS) and dihydrofolate reductase (DHFR). The study also shows the enzyme interactions with their substrates; 2'-deoxyuridine-5'-monophosphate (DUMP) and methotrexate (MTX); respectively.
Docking on the Active Site of Thymidylate Synthase
MOE docking studies of the inhibitors were performed using thymidylate synthase co-crystallized with the sub- 
Docking on the Active Site of Dihydrofolate Reductase (DHFR)
MOE docking studies of the inhibitors were performed using dihydrofolate reductase co-crystallized with me thotrexate (PDB ID: 4DFR) as a template. H-NMR spectra were recorded in (DMSO-d 6 ) at 300 MHz on a Varian Gemini NMR spectrometer (δ ppm) using TMS as an internal standard, Resarch Service Unit, Faculty of Science, Cairo University. Mass spectra were recorded on GC Ms-QP 5050A mass spectrometer at 70 eV and microanalytical data were performed on Elementar Vario EI III CHN analyzer at the microanalytical unit, in Regional center for Mycology and Biotechnology, Al-Azhar University. Thin layer chromatography was performed on precoated (0.25 mm) silica gel GF 254 plates (E. Merck, Germany). Compounds were detected with 254 nm UV lamp.
2-[2-(2-Chlorophenyl)-2-oxoethyl]quinazolin-4(3H)-one; 2
A solution of compound 1 [36] (1.6 g, 0.01 mol) in dry THF (20 mL) was added dropwise while stirring to a solution of 2-chlorobenzoyl chloride (3.5 g , 2.8 mL, 0.02 mol.) in dry THF (10 mL) at 0˚C and stirring was continued for 2 h. The reaction mixture was further stirred for 4h at room temperature then it was poured onto crushed ice. The solid obtained was filtered off, washed with water, dried and recrystallized from ethanol to yield compound 2.
White crystals, yield%: 87%, m.p.: 153˚C -155˚C, IR (KBr, cm 
5H-Quinolino[2,1-b]quinazolin-5,12-(6H)-dione; 3
A solution of compound 1 (1.6 g, 0.01 mol) in dry THF (20 mL) was added dropwise while stirring to a solution of 2-chlorobenzoyl chloride (3.5 g, 2.8 mL, 0.02 mol) in dry THF (10 mL) at 0˚C and stirring was continued for 2 h. The reaction mixture was refluxed for another 2h and the obtained product was filtered, washed with THF, dried and recrystallized from ethanol to give compound 3.
White crystals, yield %: 75% , m.p.: 300˚C -302˚C, IR (KBr, cm -1 ): 3000 (C-H aromatic); 1708, 1690 (two C=O); 1569 (C=N); 1478 (C=C). 
12H-Quinolino[2,1-b]quinazolin-12-one; 4
Equimolar amounts of compound 1 (1.6 g, 0.01 mol) and 2-chlorobenzaldehyde (1.4 g, 1.1 mL, 0.0l mol) were refluxed in glacial acetic acid (30 mL) in presence of anhydrous sodium acetate (2 g, 0.02 mol) for 8 h. The reaction mixture was allowed to cool then poured onto crushed ice. The obtained solid was filtered off, washed with water and recrystallized from ethanol to yield compound 4. [2,1-b]quinazolin-2,9(1H, 3H) -dione; 5 A solution of compound 1 (1.6 g, 0.01 mol) in dry THF (20 mL) was added dropwise while stirring to a solution of chloroacetyl chloride (2.26 g, 1.6 mL, 0.02 mol) in dry THF (10 mL) at 0˚C and stirring was continued for 2 h. The reaction mixture was further stirred for 4h at room temperature then the excess solvent was evaporated. The reaction mixture was cooled and poured onto crushed ice. The solid obtained was filtered off, washed with water, dried and recrystallized from ethanol. 
Pyrrolo
2-(4-Chlorostyryl)quinazolin-4(3H)-one; 6
Equimolar amounts of compound 1 (1.6 g, 1 mol) and 4-chlorobenzaldehyde (1.4 g, 1 mol) were refluxed in glacial acetic acid (30 mL) for 8 h in presence of anhydrous sodium acetate (2 g, 0.02 mol). The reaction mixture was allowed to cool then poured onto crushed ice. The obtained product was filtered, washed with water and recrystallized from ethanol.
White crystals, yield %: 85%, m.p: 302˚C -305˚C [41] .
4-Chloro-2-(4-chlorostyryl)quinazoline; 7
Compound 6 (3.5 g, 0.123 mol) was refluxed in excess phosphorous oxychloride (5 mL) for 14 h and in presence of a catalytic amount of triethylamine (3 -5 drops). The reaction mixture was allowed to cool then poured onto crushed ice. The obtained solid was collected. Yellowish brown, yield %: 82%, m.p.: 268˚C -270˚C [41] .
4-Amino-2-(4-chlorostyryl)quinazoline; 8
A mixture of compound 7 (3.2 g, 0.1 mol) and ammonium acetate (2.3 g, 0.3 mol) was refluxed in pyridine (30 mL) for 24 h. The reaction mixture was allowed to cool then poured onto crushed ice. 
2-(4-Chlorostyryl)-4-hydrazinylquinazoline; 9
A mixture of compound 7 (3.2 g, 1mol) and hydrazine hydrate 99% (0.5 g, 0.5 mL, 5 mol) (1:5) was refluxed in absolute ethanol (30 mL) for 8 h. The reaction mixture was allowed to cool and poured on crushed ice. The obtained solid was filtered, dried and recrystallized from acetone/ethanol. 
General Procedure for Synthesis of Compounds 11 & 12
A solution of compound 10 (0.4 g, 0.01 mol) in ethanol (30 mL) and in presence of a catalytic amount of sodium acetate (1 g, 0.01 mol) was heated under reflux for 6 h with an equimolar amount of the appropriate chloro compound namely; ethyl chloroacetate ( 0.6 g, 0.5 mL, 0.01mol) or phenacyl chloride ( 0.5 g, 0.01 mol). The solid obtained after cooling the reaction mixture was filtered off and washed with water to yield compounds 11 and 12 respectively.
1) 2-[2-(4-Chlorostyryl)quinazolin-4-ylimino]-3-phenylthiazolidin-4-one; 11
Recrystallized from ethanol, buff crystals, yield %: 43%, m.p.: 283˚C -285˚C, IR (KBr, cm Chlorostyryl)-N-(4-methyl-3-phenylthiazol-2(3H)-ylidene) quinazolin-4-amine; 13 An equimolar mixture of compound 10 (0.4 g, 0.01 mol) and chloroacetone (0.09 g, 0.1 mL, 0.01 mol) was fused at 120˚C for 24 h. The reaction mixture was triturated with ethanol. The obtained product was filtered off then washed with several solvents.
2-(4-
Black crystals, yield%: 52%, m.p.; >360˚C, IR (KBr, cm 
General Procedure for Synthesis of Compounds 14 & 15
An equimolar mixture of compound 8 (1.4 g, 0.01 mol) and phenacyl chloride (0.8 g, 0.01 mol) in ethanol (30 mL) was refluxed for 18 h. The reaction mixture was then concentrated, allowed to cool and the solid product obtained was filtered off to yield compound 14. The filtrate was poured onto crushed ice and the obtained solid was collected to give compound 15.
1) 4-Amino-2-(4-chlorostyryl)-3-(2-oxo-2-phenylethyl)quinazolin-3-ium chloride; 14
Recrystallized from ethanol, brown crystals, yield%: 64%, m.p.: 278˚C -280˚C, IR (KBr, cm -1 ): 3433 (NH 2 ); 3048 (C-H aromatic); 2921 (C-H aliphatic); 1672 (C=O); 1582 (C=N); 1460 (C=C). 
Biology
Anticancer Screening
The synthesized compounds were screened for their in vitro cytotoxic activity against human hepatocellular liver carcinoma (Hep-G2) and human breast cancer cell line (MCF-7). Doxorubicin was used as the reference drug.
Mammalian cell lines MCF-7 cells (human breast cancer cell line) were obtained from VACSERA Tissue culture unit. Hep-G2 cells (human cell line of a well differentiated hepatocellular carcinoma isolated from a liver biopsy of a male Caucasian aged 15 years) were obtained from the American type culture collection (ATCC).
Cell line Propagation
The cells were propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 1% L-glutamine, HEPES buffer and 50 µg/mL gentamycin. All cells were maintained at 37˚C in a humidified atmosphere with 5% CO 2 and were subcultured two times a week.
Cytotoxicity Evaluation Using Viability Assay
For cytotoxicity assay, the cells were seeded in 96-well plate at a cell concentration of 1 × 10 4 cells per well in 100 µL of growth medium. Fresh medium containing different concentrations of the test sample was added after 24 h of seeding. Serial two-fold dilutions of the tested chemical compound were added to confluent cell monolayers dispensed into 96-well, flat-bottomed microtiter plates (Falcon, NJ, USA) using a multichannel pipette. The microtiter plates were incubated at 37˚C in a humidified incubator with 5% CO 2 for a period of 48 h. Three wells were used for each concentration of the test sample. Control cells were incubated without test sample and with or without DMSO. The little percentage of DMSO present in the wells (maximal 0.1%) was found not to affect the experiment. After incubation of the cells for 24 h at 37˚C, various concentrations of sample (50, 25, 12.5, 6.25, 3 .125 & 1.56 µg/L) were added, and the incubation was continued for 48 h and viable cells yield was determined by a colorimetric method. After the end of the incubation period, media were aspirated and the crystal violet solution (1%) was added to each well for at least 30 minutes. The stain was removed and the plates were rinsed using tap water until all excess stain is removed. Glacial acetic acid (30%) was then added to all wells and mixed thoroughly, and then the absorbance of the plates were measured after gently shaken on Microplate reader (TECAN, Inc.), using a test wavelength of 490 nm. All results were corrected for background absorbance detected in wells without added stain. Treated samples were compared with the cell control in the absence of the tested compounds. All experiments were carried out in triplicate. The cell cytotoxic effect of each tested compound was calculated [49] [50] . The cytotoxicity of the tested compounds was estimated in terms of percent growth inhibition compared to untreated control cells and their IC 50 in µM/L which is the concentration of the compound that inhibits the tumor cell growth by 50%.
Computer Aided Docking
Materials
All the molecular studies were carried out on an Intel pentium 1.6 GHz processor, 512 MB memory with windows XP operating system using Molecular Operating Environment (MOE 2005.06; Chemical Computing Group, Montreal, Canada) as the computational software. All the minimizations were performed with MOE until a RMSD gradient of 0.05 Kcal mol -1 A 0−1 with MMFF94X forcefield and the partial charges were automatically calculated.
General Methodology
The coordinates of the X-ray crystal structure of 2'-deoxyuridine-5'-monophosphate (DUMP) bound to thymidylate synthase enzyme were obtained from Protein Data Bank (PDB ID: 1BID) as well as the coordinates of the X-ray crystal structure of methotrexate (MTX) bound to dihydrofolate reductase (DHFR) enzyme (PDB ID: 4DFR). Enzyme structures were checked for missing atoms, bonds and contacts. Hydrogen atoms were added to the enzyme structure. Water molecules and bound ligands were manually deleted. The ligand molecules were constructed using the builder molecule and were energy minimized. The active site was generated using the MOE-Alpha site finder. Dummy atoms were created from the obtained alpha spheres. Ligands were docked within the thymidylate synthase and dihydrofolate reductase active sites using the MOE-Dock with simulated annealing used as the search protocol and MMFF94X molecular mechanics forcefield for 8000 interactions. The lowest energy conformation was selected and subjected to an energy Minimization using MMFF94X force field.
Conclusion
Compounds 18, 19, 20, 23 and 24 exhibited very potent anticancer activity against both Hep-G2 and MCF-7 cell lines. However, compounds 10, 15 and 29, showed remarkable anticancer activity against liver Hep-G2 cell line, while compound 22 exhibited potent anticancer activity against MCF-7 cell line. Docking was performed for the five most active anticancer compounds 18, 19, 20, 23 and 24 on the two enzymes; thymidylate synthase and dihydrofolate reductase in a trial to predict their mode of action as anticancer drugs. Also, the compounds show several interactions with both enzymes but they exhibit strong interactions with dihydrofolate reductase enzyme, mainly compounds 18, 19, 23 and 24, giving rise to the conclusion that they might exert their action through inhibition of both enzymes but mainly DHFR enzyme.
